SG10201912869WA - Combination therapy for treating malignancies - Google Patents
Combination therapy for treating malignanciesInfo
- Publication number
- SG10201912869WA SG10201912869WA SG10201912869WA SG10201912869WA SG10201912869WA SG 10201912869W A SG10201912869W A SG 10201912869WA SG 10201912869W A SG10201912869W A SG 10201912869WA SG 10201912869W A SG10201912869W A SG 10201912869WA SG 10201912869W A SG10201912869W A SG 10201912869WA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapy
- treating malignancies
- malignancies
- treating
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242218P | 2015-10-15 | 2015-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912869WA true SG10201912869WA (en) | 2020-02-27 |
Family
ID=57219007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201802964QA SG11201802964QA (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
| SG10201912869WA SG10201912869WA (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201802964QA SG11201802964QA (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10695352B2 (en) |
| EP (1) | EP3362070B1 (en) |
| JP (1) | JP6895956B2 (en) |
| CN (1) | CN108601787B (en) |
| AU (1) | AU2016340098B2 (en) |
| BR (1) | BR112018007447B1 (en) |
| CA (1) | CA3002029A1 (en) |
| CL (1) | CL2018000955A1 (en) |
| EA (1) | EA036129B1 (en) |
| ES (1) | ES2862730T3 (en) |
| IL (1) | IL258580B (en) |
| MX (1) | MX2018004599A (en) |
| SG (2) | SG11201802964QA (en) |
| WO (1) | WO2017066611A1 (en) |
| ZA (1) | ZA201802420B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9993172B2 (en) | 2013-12-09 | 2018-06-12 | Medtronic, Inc. | Noninvasive cardiac therapy evaluation |
| MX2016011810A (en) | 2014-03-14 | 2017-04-27 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds. |
| KR20180061372A (en) | 2015-10-15 | 2018-06-07 | 아지오스 파마슈티컬스 아이엔씨. | Combination Therapy for the Treatment of Malignant Tumors |
| SI3362066T1 (en) * | 2015-10-15 | 2022-04-29 | Les Laboratoires Servier | Combination therapy for treating malignancies |
| AU2016340087C1 (en) | 2015-10-15 | 2022-08-18 | Les Laboratoires Servier | Combination therapy for treating malignancies |
| US11219769B2 (en) | 2016-02-26 | 2022-01-11 | Medtronic, Inc. | Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing |
| WO2018048847A1 (en) | 2016-09-07 | 2018-03-15 | Celgene Corporation | Tablet compositions |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| MX2019014934A (en) * | 2017-06-12 | 2022-06-28 | Agios Pharmaceuticals Inc | Methods of treating brain tumors using combination therapy. |
| BR112020000492A2 (en) * | 2017-07-09 | 2020-07-14 | Biosight Ltd. | combination cancer therapy |
| CN111902082A (en) | 2018-03-29 | 2020-11-06 | 美敦力公司 | Left ventricular assist device adjustment and evaluation |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US20210403452A1 (en) | 2018-11-02 | 2021-12-30 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
| SG11202110702WA (en) * | 2019-04-29 | 2021-11-29 | Immunogen Inc | Therapeutic combinations comprising anti-cd123 immunoconjugates |
| US11497431B2 (en) | 2019-10-09 | 2022-11-15 | Medtronic, Inc. | Systems and methods for configuring cardiac therapy |
| EP4058028A1 (en) | 2019-11-14 | 2022-09-21 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN111087408B (en) * | 2020-01-03 | 2021-04-02 | 浙江大学 | Macrocyclic IDH2 mutant inhibitor and medical application thereof |
| US20240229156A1 (en) * | 2021-03-12 | 2024-07-11 | Celgene Corporation | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| EP1251832B1 (en) | 2000-02-04 | 2006-09-27 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US7038038B2 (en) * | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| US8846628B2 (en) * | 2008-05-15 | 2014-09-30 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| ES2401951T3 (en) * | 2008-06-09 | 2013-04-25 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| JP6067226B2 (en) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | Methods and compositions for cell proliferation related diseases |
| WO2011050211A2 (en) * | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| EP2773360B1 (en) * | 2011-11-03 | 2018-02-28 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
| PT2800743T (en) | 2012-01-06 | 2018-07-04 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| WO2015006592A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| US9738625B2 (en) | 2013-08-02 | 2017-08-22 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| JP2017529382A (en) | 2014-09-29 | 2017-10-05 | アギオス ファーマシューティカルス，インコーポレーテッド | Compounds having therapeutic activity and methods of use thereof |
| CN107531675A (en) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | Therapeutical active compound and its application method |
| CN108349933A (en) | 2015-08-05 | 2018-07-31 | 安吉奥斯医药品有限公司 | The method for preparing 6- (aryl or heteroaryl) -1,3,5- triazine -2,4- glycol and 6- (aryl or heteroaryl) -1,3,5- triazine -2,4- diamines |
| AU2016340087C1 (en) | 2015-10-15 | 2022-08-18 | Les Laboratoires Servier | Combination therapy for treating malignancies |
| CA3007218A1 (en) | 2015-12-04 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
| WO2017146794A1 (en) | 2016-02-26 | 2017-08-31 | Celgene Corporation | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
-
2016
- 2016-10-14 JP JP2018519352A patent/JP6895956B2/en active Active
- 2016-10-14 ES ES16788866T patent/ES2862730T3/en active Active
- 2016-10-14 EP EP16788866.8A patent/EP3362070B1/en active Active
- 2016-10-14 WO PCT/US2016/057102 patent/WO2017066611A1/en active Application Filing
- 2016-10-14 CN CN201680072973.3A patent/CN108601787B/en active Active
- 2016-10-14 US US15/768,462 patent/US10695352B2/en active Active
- 2016-10-14 AU AU2016340098A patent/AU2016340098B2/en active Active
- 2016-10-14 SG SG11201802964QA patent/SG11201802964QA/en unknown
- 2016-10-14 CA CA3002029A patent/CA3002029A1/en not_active Abandoned
- 2016-10-14 SG SG10201912869WA patent/SG10201912869WA/en unknown
- 2016-10-14 BR BR112018007447-0A patent/BR112018007447B1/en active IP Right Grant
- 2016-10-14 MX MX2018004599A patent/MX2018004599A/en unknown
- 2016-10-14 EA EA201890961A patent/EA036129B1/en not_active IP Right Cessation
-
2018
- 2018-04-09 IL IL258580A patent/IL258580B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02420A patent/ZA201802420B/en unknown
- 2018-04-13 CL CL2018000955A patent/CL2018000955A1/en unknown
-
2020
- 2020-05-21 US US16/880,871 patent/US20210100805A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL258580B (en) | 2021-05-31 |
| CA3002029A1 (en) | 2017-04-20 |
| JP2018535951A (en) | 2018-12-06 |
| EA201890961A1 (en) | 2018-11-30 |
| US10695352B2 (en) | 2020-06-30 |
| MX2018004599A (en) | 2018-09-21 |
| IL258580A (en) | 2018-05-31 |
| EA036129B1 (en) | 2020-10-01 |
| AU2016340098A1 (en) | 2018-05-10 |
| WO2017066611A1 (en) | 2017-04-20 |
| ES2862730T3 (en) | 2021-10-07 |
| KR20180064529A (en) | 2018-06-14 |
| CL2018000955A1 (en) | 2018-09-14 |
| JP6895956B2 (en) | 2021-06-30 |
| ZA201802420B (en) | 2020-08-26 |
| CN108601787B (en) | 2022-07-29 |
| US20210100805A1 (en) | 2021-04-08 |
| US20180303840A1 (en) | 2018-10-25 |
| EP3362070A1 (en) | 2018-08-22 |
| CN108601787A (en) | 2018-09-28 |
| EP3362070B1 (en) | 2021-01-27 |
| SG11201802964QA (en) | 2018-05-30 |
| BR112018007447B1 (en) | 2023-12-05 |
| AU2016340098B2 (en) | 2022-06-02 |
| BR112018007447A2 (en) | 2018-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802420B (en) | Combination therapy for treating malignancies | |
| ZA201803166B (en) | Combination therapy for treating malignancies | |
| IL254705B (en) | Combination therapy for cancer | |
| IL251464A0 (en) | Combination therapy for cancer | |
| ZA201802088B (en) | Combination therapy for treating malignancies | |
| IL255060A0 (en) | Combination therapy for treating cancer | |
| IL258684A (en) | Combination therapy for treating malignancies | |
| HK1259342A1 (en) | Combination therapies for treating cancer | |
| HK1231381A1 (en) | Combination therapy for cancer | |
| IL246761A0 (en) | Combination therapy for cancer | |
| HK1254687A1 (en) | Combination therapy for cancer | |
| HRP20210383T8 (en) | Combination therapy for cancer | |
| HK1256371A1 (en) | Methods for treating tumours | |
| GB201417819D0 (en) | Agents for cancer therapy |